

Guideline Page and Request	Panel Discussion/References	Institution Vote			
		YES	NO	Abstain	Absent
<p><b>MYEL-F (3 of 3)</b></p> <p>Internal request: In response to the FDA approval of isatuximab-irfc in combination with pomalidomide and dexamethasone for the treatment of adult patients diagnosed with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, request was to add isatuximab-irfc in combination with pomalidomide and dexamethasone as a treatment option for this indication.</p> <p>External request: Submission from Sanofi on March 2<sup>nd</sup>, 2020 to include isatuximab-irfc as a treatment option for management of adult patients with relapsed/refractory multiple myeloma.</p>	<p>Based on the review of the data in the noted references and the recent FDA approval, the panel consensus was to include isatuximab-irfc, in combination with pomalidomide and dexamethasone, as an option for patients diagnosed with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. This is a category 1 recommendation included under other recommended regimen.</p> <p>See Submission for references.</p>	18	2	1	7